Literature DB >> 17043487

Infliximab treatment of Familial Mediterranean fever and its effect on secondary AA amyloidosis.

Samy Metyas1, Daniel G Arkfeld, Deborah M Forrester, Glenn R Ehresmann.   

Abstract

We describe a patient with a long history of familial Mediterranean fever who developed proteinuria as a result of secondary AA amyloidosis. In this patient, the inflammatory process, including recurrent attacks of arthritis, abdominal pain, nephrotic syndrome secondary to amyloidosis, and high sedimentation rate, was rapidly suppressed by treatment with infliximab and there was remarkable improvement of the proteinuria.Because TNF-alpha is a proinflammatory cytokine that plays a major role in FMF and secondary amyloid, it is an appropriate target for therapy. Our case is the first case of reactive systemic amyloidosis secondary to familial Mediterranean fever, which responded favorably to infliximab.

Entities:  

Year:  2004        PMID: 17043487     DOI: 10.1097/01.rhu.0000128856.13595.eb

Source DB:  PubMed          Journal:  J Clin Rheumatol        ISSN: 1076-1608            Impact factor:   3.517


  11 in total

1.  [Autoinflammatory syndromes/fever syndromes].

Authors:  J Schedel; B Bach; J B Kümmerle-Deschner; I Kötter
Journal:  Hautarzt       Date:  2011-05       Impact factor: 0.751

2.  Successful treatment with anti-tumor necrosis factor (anti-TNF)-alpha of proteinuria in a patient with familial mediterranean fever (FMF) resistant to colchicine: anti-TNF drugs and FMF.

Authors:  S Erten; S F Erten; A Altunoglu
Journal:  Rheumatol Int       Date:  2011-03-23       Impact factor: 2.631

Review 3.  Infliximab therapy for familial Mediterranean fever-related amyloidosis: case series with long term follow-up.

Authors:  Z Birsin Özçakar; Selçuk Yüksel; Mesiha Ekim; Fatoş Yalçınkaya
Journal:  Clin Rheumatol       Date:  2012-06-07       Impact factor: 2.980

4.  TNF/TNFR axis promotes pyrin inflammasome activation and distinctly modulates pyrin inflammasomopathy.

Authors:  Deepika Sharma; Ankit Malik; Clifford Guy; Peter Vogel; Thirumala-Devi Kanneganti
Journal:  J Clin Invest       Date:  2018-11-19       Impact factor: 14.808

Review 5.  [Periodic fever syndrome/autoinflammatory syndrome].

Authors:  I Kötter; J Schedel; J B Kümmerle-Deschner
Journal:  Z Rheumatol       Date:  2009-03       Impact factor: 1.372

6.  Familial Mediterranean fever: the first adult case in Korea.

Authors:  Ah Leum Lim; Hyun Joo Jang; Jung Wan Han; Yong Keun Song; Won Jun Song; Heung Jung Woo; Young Ok Jung; Sea Hyub Kae; Jin Lee
Journal:  J Korean Med Sci       Date:  2012-10-30       Impact factor: 2.153

Review 7.  Does protein aggregation drive postmitotic tissue degeneration?

Authors:  Jeffery W Kelly
Journal:  Sci Transl Med       Date:  2021-01-20       Impact factor: 19.319

Review 8.  Biological treatments: new weapons in the management of monogenic autoinflammatory disorders.

Authors:  Antonio Vitale; Donato Rigante; Orso Maria Lucherini; Francesco Caso; Isabella Muscari; Flora Magnotti; Maria Giuseppina Brizi; Susanna Guerrini; Maria Patti; Leonardo Punzi; Mauro Galeazzi; Luca Cantarini
Journal:  Mediators Inflamm       Date:  2013-07-21       Impact factor: 4.711

Review 9.  Off-label uses of anti-TNF therapy in three frequent disorders: Behçet's disease, sarcoidosis, and noninfectious uveitis.

Authors:  Daniel Sánchez-Cano; José Luis Callejas-Rubio; Ricardo Ruiz-Villaverde; Raquel Ríos-Fernández; Norberto Ortego-Centeno
Journal:  Mediators Inflamm       Date:  2013-08-01       Impact factor: 4.711

10.  Recurrence of proteinuria after cessation of tocilizumab in patients with AA amyloidosis secondary to FMF.

Authors:  Sedat Yılmaz; Emre Tekgöz; Muhammet Çınar
Journal:  Eur J Rheumatol       Date:  2018-07-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.